Madrigal pharmaceuticals reports inducement grants under nasdaq listing rule 5635(c)(4)

Conshohocken, pa., april 03, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that the company granted equity awards to 30 new employees, in each case with a grant date of april, 1 2024, as equity inducement awards under the terms of the company's 2023 inducement plan. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4).
MDGL Ratings Summary
MDGL Quant Ranking